Compound ID | 1208
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | RNA polymerase inhibitor (new binding site; different from binding sites for rifampin and fidaxomicin) |
| Combined with other compounds: | yes |
| Propensity to select resistant mutants: | yes |
| Institute where first reported: | Rutgers University |
| Year first mentioned: | 2016 |
| Highest development stage: | Preclinical |
| Development status: | Active |
| External links: | |
| Citations: |
|
| Patent: | US11685723B2 |